These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 31625704)

  • 1. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    De Vecchis R; Paccone A; Di Maio M
    Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan Therapy for 14 Months Induces a Marked Improvement of Global Longitudinal Strain in Patients With Chronic Heart Failure: A Retrospective Cohort Study.
    De Vecchis R; Paccone A; Di Maio M
    Cardiol Res; 2019 Oct; 10(5):293-302. PubMed ID: 31636797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
    Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
    J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report.
    Kuwae N
    CEN Case Rep; 2024 Aug; 13(4):233-239. PubMed ID: 37995053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.
    Lee WC; Liao TW; Chen TY; Fang HY; Fang YN; Chen HC; Lin YS; Chang SH; Chen MC
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):505-515. PubMed ID: 36609948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan.
    Lin PL; Lee YH; Liu LY; Tsai CT; Yang TF; Chiou WR; Hsieh MY; Chang HY; Huang CC
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221107799. PubMed ID: 35713466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
    Camilli M; Iannaccone G; Russo M; Meucci MC; Chiorazzo G; Natali R; Mango F; Bonanni A; Montone RA; Graziani F; Locorotondo G; Massetti M; Lanza GA; Aspromonte N; Crea F; Lombardo A
    Int J Cardiol; 2023 Sep; 387():131110. PubMed ID: 37290664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
    Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
    J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Amin OA; Alaarag AF
    Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
    Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
    J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.
    Moon MG; Hwang IC; Lee HJ; Kim SH; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ; Cho GY
    JACC Cardiovasc Imaging; 2022 Sep; 15(9):1525-1541. PubMed ID: 36075612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
    Biering-Sørensen T; Lassen MCH; Shah A; Claggett B; Zile M; Pieske B; Pieske-Kraigher E; Voors A; Shi V; Lefkowitz M; Packer M; McMurray JJV; Solomon SD;
    J Card Fail; 2023 Jun; 29(6):968-973. PubMed ID: 37031887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
    Lund LH; Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Kalus S; Ferber PC; Koch C; Maggioni AP;
    Int J Cardiol; 2023 Jan; 370():279-286. PubMed ID: 36216094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
    Abumayyaleh M; Demmer J; Krack C; Pilsinger C; El-Battrawy I; Behnes M; Aweimer A; Mügge A; Lang S; Akin I
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):535-544. PubMed ID: 35353351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.